<DOC>
	<DOCNO>NCT00938574</DOCNO>
	<brief_summary>This phase I , prospective , open-label , single center , dose find study Atu027 ( siRNA formulation ) give single treatment follow repeat treatment ( repeat treatment phase : 8 treatment within 4 week ) therapy subject advance solid cancer .</brief_summary>
	<brief_title>Study With Atu027 Patients With Advanced Solid Cancer</brief_title>
	<detailed_description />
	<criteria>1 . Histologically and/or cytologically proven advanced , recurrent metastatic solid malignancy standard curative palliative measure exist , longer effective , unlikely effective . 2 . Age &gt; /= 18 year . 3 . ECOG performance score 02 . 4 . Life expectancy least 3 month . 5 . Subjects must recover acute reversible effect previous anticancer therapy . At least 30 day since major surgery least 5 halflives ( t1/2 ) must elapse since treatment investigational agent . 6 . Adequate marrow , hepatic , renal , heart function time screen . 7 . Weight &gt; /= 50kg . 8 . Subjects must least one measurable lesion accord RECIST . 9 . Women childbearing potential must negative urine pregnancy test baseline . 10 . Women childbearing potential men must willing use highly effective contraceptive method course study three month . 11 . Subjects must willing able ( opinion investigator ) understand subject information inform consent form comply study protocol procedure . 12 . Subjects must willing able give write informed consent . 1 . Evidence central nervous system ( CNS ) metastases . 2 . Peripheral venous access insufficient permit intravenous infusion acquisition laboratory specimen . 3 . Major surgery within 30 day prior first study treatment . 4 . Evidence subject insufficiently recover acute reversible effect previous anticancer therapy surgery . 5 . Abnormal hematologic parameter define : Neutrophil count &lt; 1.500/mm3 ( =1.5x10^9/l ) Platelet count &lt; 100.00/mm3 ( =100x10^9/l ) White blood cell &lt; 3x10^9/l Hemoglobin &lt; 9.0 g/l 6 . Abnormal renal hepatic function define : ASAT ( SGOT ) , ALAT ( SGPT ) &gt; /= 1.5xULN &gt; /= 2.0xULN case liver metastasis Total bilirubin &gt; /= 1.5xULN Creatinine clearance &lt; 50ml/min calculated CockroftGault formula 7 . Weight &lt; 50 kg . 8 . Any concurrent disease , medical social condition could affect compliance protocol interpretation result judge investigator . In particular , subject follow condition allow enter study : Seizures Poorly control Diabetes mellitus Lipid metabolism disorder ( cholesterol triglycerides &gt; /= 1.5xULN ) , Refsum disease Myocardial infarction within six ( 6 ) month prior enrollment insufficient cardiac function define NYHA Grade 3 4 , uncontrolled angina , cardiomyopathy , severe uncontrolled ventricular arrhythmia , leave bundle branch block electrocardiographic evidence acute ischemic active conduction system abnormality ( e.g . long QT interval , Torsade de Pointes ) Poorly control hypertension Severe dyspnea severe pulmonary dysfunction Autoimmune inflammatory disease Active infection know bacteremia Known infection HIV chronic infection hepatitis B C virus History acute chronic pancreatitis Substance abuse 9 . Prior gene transfer therapy . 10 . Concurrent treatment investigational commercial agent therapy administer intention treat subject 's malignancy . 11 . Participation clinical study use investigational device ( ) participation study . 12 . Known hypersensitivity ingredient infusion solution . 13 . Pregnant nursing woman woman childbearing potential willing use highly effective form contraception participation study least three month thereafter . 14 . Male subject partner childbearing potential willing use highly effective contraception participation study least three month thereafter , unless surgically sterile . 15 . Subject relative , staff directly report investigator employee sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>